Stuart A. Aaronson
|Stuart A. Aaronson, M.D.|
February 28, 1942|
Mount Clemens, Michigan
|Alma mater||UC Berkeley, UC SF|
|Employer||Mount Sinai Medical Center|
|Known for||Cancer research|
|Title||Jane B. and Jack R. Aron Professor of Neoplastic Diseases and Founding Chair Emeritus of Oncological Sciences|
Stuart A. Aaronson, M.D., is an American author and internationally recognized cancer biologist. He has authored more than 500 publications and holds over 50 patents, and was the Jane B. and Jack R. Aron Professor of Neoplastic Diseases and Chairman of Oncological Sciences at Mount Sinai Medical Center in New York City until March 2013, when he assumed the title of Founding Chair Emeritus of the Department of Oncological Sciences. The current Chairman of Oncological Sciences is Ramon E. Parsons.
Aaronson graduated summa cum laude from the University of California, Berkeley, in 1962, with a degree in chemistry. He earned his M.D. from the University of California, San Francisco Medical Center in 1966, and completed a fellowship at the University of Cambridge in England and an internship in medicine at Moffitt Hospital in San Francisco.
In 1967, Aaronson joined the National Institutes of Health as a Senior Staff Fellow. He headed the Molecular Biology Section of the Viral Carcinogenesis Branch from 1970 until 1977, after which he became Chief of the Laboratory of Cellular and Molecular Biology at the National Cancer Institute, until 1993, when he was named Chairman of Oncological Sciences at Mount Sinai Medical Center.
Aaronson's early research established the transformation-competent but replication-defective nature of mammalian sarcoma viruses and molecularly cloned many of their oncogenes. His investigations of the v-sis oncogene established the first normal function of an oncogene and its role in growth factor signaling. His discovery of erbB2 as a v-erbB-related gene amplified in a human breast carcinoma and the demonstration of its transforming properties paved the way for targeted therapies directed against its product, and his successful isolation of KGF (FGF7), a growth factor present in the epithelialization-phase of wound healing, led to Amgen's successful phase III clinical trial and FDA approval of KGF for treatment of mucositis. Current research includes investigations into the mechanisms by which tumor suppressor genes induce permanent growth arrest/senescence, the signaling pathways involved, and investigations of the autocrine and paracrine acting growth factors PDGF, KGF, HGF, and Wnt ligands.
Awards and honors
- 1982 Rhoads Memorial Award
- 1982 PHS Meritorious Service Medal
- 1989 Paul Ehrlich Award
- 1989 PHS Distinguished Service Medal
- 1990 Milken Award
- 1991 Chirone Prize
- 1991 Harvey Lecture
- 1991 Wadsworth Memorial Foundation Award
- 2005 FLC Mid-Atlantic Regional Excellence in Technology Transfer Award – Kepivance
- 2006 National FLC Award for Excellence in Technology Transfer – Kepivance: Improving the Quality of Life for Cancer Patients
|6479255||Polynucleotides encoding human FRP and fragments thereof|
|6225088||DNA encoding plasminogen-like growth factor (PLGF) and related embodiments|
|6228600||Immunoassays for the alpha platelet-derived growth factor receptor|
|6403769||Fusion proteins that include antibody and nonantibody portions|
|6566098||DNA encoding truncated hepatocyte growth factor variants|
|6639060||erbB-3 nucleic acids|
|6653084||Anti-erbB-2 antibodies to human receptor related to but distinct from EGF receptor|
|6660488||Antibodies for the alpha platelet-derived growth factor receptor|
|6709842||DNA encoding a growth factor specific for epithelial cells|
|6833132||Method of stimulating epithelial cells using keratinocyte growth factor (KGF) and method of inhibiting KGF activity|
- Asciutti S, Akiri G, Grumolato L, Vijayakumar S, Aaronson S (2011). "Diverse mechanisms of Wnt activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells". Oncogene 30: 956–966. doi:10.1038/onc.2010.475. PMID 21042278.
- Akiri G, Cherian M, Vijayakumar S, Liu G, Bafico A, Aaronson S (2009). "Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma". Oncogene 28: 2163–2172. doi:10.1038/onc.2009.82. PMID 19377513.
- Liu G, Grumolato L, Arroyave R, Qiao H, Akiri G, Aaronson S. "Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells." Journal of Cell Biology 2009 April; 185(1): 67-75. doi:10.1083/jcb.200810137 PMID 19349579
- Zhao B, Benson E, Qiao R, Wang X, Kim S, Manfredi J, Lee S, Aaronson S. "Cellular senescence and organismal ageing in the absence of p21 CIP1/WAF1 in ku80-/-mice." EMBO 2009;: 71-78. doi:10.1038/embor.2008.220 PMID 19079133
- Ongusaha PP, Qi HH, Raj L, Kim YB, Aaronson SA, Davis R, Shi Y, Liao J, Lee SW. "Identification of ROCK1 as an Upstream Activator of the JIP-3 to JNK Signaling Axis in Response to UVB Damage." Sci Signal 25 November 2008; 1(47): ra14. doi:10.1126/scisignal.1161938 PMID 19036714
- Munoz-Fontella C, Macip S, Martinez-Sobrido L, Brown L, Ashour J, Garcia-Sastre A, Lee SW, Aaronson SA. "Transcriptional role of p53 in Interferon-mediated antiviral immunity." Journal of Exp. Med 2008 July;: 1-10. doi:10.1084/jem.20080383 PMID 18663127
- Mahale A, Khan Z, Igarashi M, Nanjangud G, Qiao RF, Yao S, Lee SW, Aaronson SA (2008). "Clonal Selection in Malignant Transformation of Human Fibroblasts Transduces with Defined Cellular Oncogenes". Cancer Research 68 (5): 1417–1426. doi:10.1158/0008-5472.CAN-07-3021. PMID 18316605.
- Brown L, Ongusaha P, Kim H, Nuti S, Mandinova A, Lee J, Khosravi-Far R, Aaronson SA, Lee S. et al. (2007). "CDIP, a novel pro-apoptotic gene, regulates TNFalpha-mediated apoptosis in a p53-dependent manner". The EMBO Journal 26 (14): 3410–3422. doi:10.1038/sj.emboj.7601779. PMC 1933410. PMID 17599062.
- Das S, Raj L, Zhao B, Bernstein A, Aaronson SA, Lee SA (2007). "Hzf, a key modulator of p53 mediated transcription, functions as a critical determinant of cell survival and death upon genotoxic stress". Cell 130: 624–637. doi:10.1016/j.cell.2007.06.013. PMC 2779720. PMID 17719541.
- "ACGT - Scientific Advisory Council - Stuart A. Aaronson, M.D.". Retrieved 2010-01-06.[dead link]
- "Breast Cancer Research Foundation: Stuart Aaronson". Retrieved 2010-01-06.[dead link]
- "Mount Sinai School of Medicine - Faculty profile". Retrieved 2010-01-06.
- "The Black Family Stem Cell Institute". Retrieved 2010-01-06.
- "Human Keratinocyte Growth Factor (KGF) from GenWay Biotech, Inc. - Biocompare". Retrieved 2010-01-06.
- Ulich TR, Yi ES, Cardiff R, et al. (May 1994). "Keratinocyte growth factor is a growth factor for mammary epithelium in vivo. The mammary epithelium of lactating rats is resistant to the proliferative action of keratinocyte growth factor.". Am. J. Pathol. 144 (5): 862–8. PMC 1887355. PMID 8178937.
- "United States Patent: 6479255".
- "United States Patent: 6225088".
- "United States Patent: 6228600".
- "United States Patent: 6403769".
- "United States Patent: 6566098".
- "United States Patent: 6639060".
- "United States Patent: 6653084".
- "United States Patent: 6660488".
- "United States Patent: 6709842".
- "United States Patent: 6833132".
- Mount Sinai Medical Center homepage
- Mount Sinai School of Medicine homepage
- Activation of a Cancer Gene by Single Mutation Reported. The New York Times, September 28, 1983
- Cancer Gene Linked to Flaws in Growth of an Ordinary Cell. The New York Times, February 10, 1984
- The Long Road: Scientists worked for years to unravel Met's role in cancer. Cover story, Chemical & Engineering News, August 20, 2007
Retraction of Molecular Cell 36, 379–392; November 13, 2009 in Molecular Cell, Volume 51, Issue 4, 552, 22 August 2013